Ocular Therapeutix (NSDQ:OCUL) has closed an underwritten public offering of 7,475,000 shares of its common stock at $5.00 apiece, reeling in $35.1 million to fund the planned resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year.
The Bedford, Mass.-based company also plans to use its newly-acquired funds to support the clinical development of its pipeline and prepare for regulatory submission of its other product candidates.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix closes $35m offering appeared first on MassDevice.
from MassDevice http://ift.tt/2BDeCfG
Cap comentari:
Publica un comentari a l'entrada